Seasonal Malaria Chemoprevention Therapy in Children Up To 9 Years of Age: Protocol for a Cluster-Randomized Trial Study (Preprint)
Authors:
- Mahamoudou ToureMTMahamoudou Toure
- Jeffrey G ShafferJSJeffrey G Shaffer
- Daouda SanogoDSDaouda Sanogo
- Soumba KeitaSKSoumba Keita
- Moussa KeitaMKMoussa Keita
- Fousseyni KaneFKFousseyni Kane
- Bourama TraoreBTBourama Traore
- Djeneba DabitaoDDDjeneba Dabitao
- Aissata KoneAKAissata Kone
- Cheick Oumar DoumbiaCDCheick Oumar Doumbia
- Joseph KeatingJKJoseph Keating
- Joshua YukichJYJoshua Yukich
Preprint
- 7 August 2023
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND Seasonal malaria chemoprevention (SMC) is recommended by the World Health Organization for the sub-Sahel region in sub-Saharan Africa for preventing malaria in children 3 months old to younger than 5 years. Since 2016, the Malian National Malaria Control Program has deployed SMC countrywide during its high malaria transmission season at a rate of 4 monthly cycles annually. The standard SMC regimen includes sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ). Resistance against SP is suspected to be rising across West Africa; therefore, assessing the effectiveness of an alternative antimalarial drug for SMC is needed to provide a second-line regimen when it is ultimately needed. It is not well understood whether SMC effectively prevents malaria in children aged 5 years or older. OBJECTIVE The primary goal of the study is to compare 2 SMC regimens (SP-AQ and dihydroartemisinin-piperaquine [DHA-PQ]) in preventing uncomplicated Plasmodium falciparum malaria in children 3 months to 9 years old. Secondly, we will assess the possible use of DHA-PQ as an alternative SMC drug in areas where resistance to SP or AQ may increase following intensive use. METHODS The study design is a 3-arm cluster-randomized design comparing the SP-AQ and DHA-PQ arms in 2 age groups (younger than 5 years and 5-9 years) and a control group for children aged 5-9 years. Standard SMC (SP-AQ) for children younger than 5 years was provided to the control arm, while SMC with SP-AQ was delivered to children aged 3 months to 9 years (arm 2), and SMC with DHA-PQ will be implemented in study arm 3 for children up to 9 years of age. The study was performed in Mali’s Koulikoro District, a rural area in southwest Mali with historically high malaria transmission rates. The study’s primary outcome is P falciparum incidence for 2 SMC regimens in children up to 9 years of age. Should DHA-PQ provide an acceptable alternative to SP-AQ, a plausible second-line prevention option would be available in the event of SP resistance or drug supply shortages. A significant byproduct of this effort included bolstering district health information systems for rapid identification of severe malaria cases. RESULTS The study began on July 1, 2019. Through November 2022, a total of 4556 children 3 months old to younger than 5 years were enrolled. Data collection ended in spring 2023, and the findings are expected to be published later in early 2024. CONCLUSIONS Routine evaluation of antimalarial drugs is needed to establish appropriate SMC age targets. The study goals here may impact public health policy and provide alternative therapies in the event of drug shortages or resistance. CLINICALTRIAL ClinicalTrials.gov NCT04149106, https://clinicaltrials.gov/ct2/show/NCT04149106 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/51660Keywords
All Related Versions
- Published version: JMIR Research Protocols, 13, e51660.
This publication has 14 references indexed in Scilit:
- A comprehensive analysis of drug resistance molecular markers and Plasmodium falciparum genetic diversity in two malaria endemic sites in MaliMalaria Journal, 2019
- Genetic diversity and drug resistance surveillance of Plasmodium falciparum for malaria elimination: is there an ideal tool for resource-limited sub-Saharan Africa?Malaria Journal, 2019
- Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young childrenNature Communications, 2019
- Changes in Malaria Epidemiology in Africa and New Challenges for EliminationTrends in Parasitology, 2017
- Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina FasoAntimicrobial Agents and Chemotherapy, 2015
- Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina FasoAntimicrobial Agents and Chemotherapy, 2014
- Monitoring antifolate resistance in intermittent preventive therapy for malariaTrends in Parasitology, 2013
- Age-Patterns of Malaria Vary with Severity, Transmission Intensity and Seasonality in Sub-Saharan Africa: A Systematic Review and Pooled AnalysisPLOS ONE, 2010
- Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysisThe Lancet, 2008
- Malaria transmission dynamics in Niono, Mali: The effect of the irrigation systemsActa Tropica, 2007